BMRN · Biomarin Pharmaceutical Inc
$66.83
-0.86 (-1.26%)
At close · Aug 21
Market Cap
$13.10B
Shares
193.57M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$67.68
Open$68.11
Day$67.57–68.75
52W close$49.67–70.24
Avg vol 30d2.1M
Short int12.5M · 6.5% float · 7.4d
Short vol54%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
+12%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
88%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
+10%
trailing
YTD return
+14%
this year
Relative strength
−2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $60 › 200d $57 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +88 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.46% of float · ▼ -12.7% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
564 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+18%
Y/Y
EPS growth
−19%
Y/Y
Free cash flow
$725.0M
Valuation
P/E 173.5
rich
Balance sheet
$714.5M
net cash
Quant / Vol
risk profile
Volatility
35%
annualized · 1-yr
Max drawdown
−22%
past year
ATR
3.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
mid-2030s
Peak revenue
$1.4B
Combined peak revenue potential
$2.6B
mid to late 2030s
Peak revenue
$1.2B
2028
Cost synergies
$220M
2030
Non-GAAP operating margin
Non-GAAP
60%
Prior guidance
period ended
· from the 8-K filed Oct 27, 2025
Non-GAAP Diluted EPS
· full-year 2025
$3.50 – $3.60
Guided vs delivered
· last 1 settled
Total revenues
2024
guided up to $3B
$2.85B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
+12%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
88%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $60 › 200d $57 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +88 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.46% of float · ▼ -12.7% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
564 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $50
Now $68 · 88%
Range high $70
vs 200-day avg +18%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Income from Operations non-GAAP | $545M | Six Months Ended June 30, 2026 | — |
| Non-GAAP Operating Margin non-GAAP | 31% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Operating cash flows | $221M | first quarter 2026 | — |
|
|
|||
| Total cash | $2B | the end of the first quarter 2026 | — |
| Non-convertible debt financing | $3.7B | full year 2025 | — |
| VOXZOGO commercial markets | 55 | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BMRN
this stock
Biomarin Pharmaceutical Inc
|
$13.10B | +13.9% | +17.6% | 173.5 | 6.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BMRN | -1.2% | +15.0% | +9.6% | +12.8% | +13.9% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +0.7% | +11.7% | -1.5% | +10.7% | +2.1% |
Key facts
CIK
1048477
CUSIP
09061G101
13F (30d)
521 filings
490 filers
Visit website
Investor relations